Xiang‐Qing Yu

1.3k total citations
21 papers, 980 citations indexed

About

Xiang‐Qing Yu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Xiang‐Qing Yu has authored 21 papers receiving a total of 980 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Immunology. Recurrent topics in Xiang‐Qing Yu's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Xiang‐Qing Yu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Xiang‐Qing Yu collaborates with scholars based in United States, Germany and Slovakia. Xiang‐Qing Yu's co-authors include Gabriel J. Robbie, Ashley Keller, C. Kendall Stover, William F. Dall’Acqua, Vaheh Oganesyan, Hasan S. Jafri, Yuling Wu, Terramika Bellamy, Vivekananda Datta and Jamese J. Hilliard and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Xiang‐Qing Yu

21 papers receiving 911 citations

Peers

Xiang‐Qing Yu
Yuling Wu United States
Chandresh Sharma India
Xiaoxue Ma China
Supriya Pokkali United States
Thibaud Koessler Switzerland
John G. Chosay United States
David E. Tabor United States
La‐Gen Wan China
Govindarajan Rajagopalan United States
Yuling Wu United States
Xiang‐Qing Yu
Citations per year, relative to Xiang‐Qing Yu Xiang‐Qing Yu (= 1×) peers Yuling Wu

Countries citing papers authored by Xiang‐Qing Yu

Since Specialization
Citations

This map shows the geographic impact of Xiang‐Qing Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiang‐Qing Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiang‐Qing Yu more than expected).

Fields of papers citing papers by Xiang‐Qing Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiang‐Qing Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiang‐Qing Yu. The network helps show where Xiang‐Qing Yu may publish in the future.

Co-authorship network of co-authors of Xiang‐Qing Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiang‐Qing Yu. A scholar is included among the top collaborators of Xiang‐Qing Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiang‐Qing Yu. Xiang‐Qing Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ali, Omar, Xiang‐Qing Yu, Gabriel J. Robbie, et al.. (2018). Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clinical Microbiology and Infection. 25(5). 629.e1–629.e6. 92 indexed citations
2.
3.
Shan, Lu, Xiang‐Qing Yu, Jared S. Bee, et al.. (2016). Generation and Characterization of an IgG4 Monomeric Fc Platform. PLoS ONE. 11(8). e0160345–e0160345. 14 indexed citations
4.
Hamilton, Erika, Manish R. Patel, Mark D. Pegram, et al.. (2016). A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS632–TPS632. 2 indexed citations
5.
Li, Jiapeng, Yu Liu, Xiang‐Qing Yu, et al.. (2016). Reduced Oral Bioavailability and Altered Pharmacokinetics of Saquinavir by Co-administration with Biochanin A in Rats. Drug Research. 66(9). 484–488. 2 indexed citations
6.
Yu, Xiang‐Qing, Gabriel J. Robbie, Yuling Wu, et al.. (2016). Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 61(1). 104 indexed citations
7.
Bezabeh, Binyam, Ryan Fleming, Christine Fazenbaker, et al.. (2016). Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. mAbs. 9(2). 240–256. 16 indexed citations
8.
Mazor, Yariv, Vaheh Oganesyan, Chunning Yang, et al.. (2015). Improving target cell specificity using a novel monovalent bispecific IgG design. mAbs. 7(2). 377–389. 108 indexed citations
9.
Zheng, Bo, Xiang‐Qing Yu, Warren Greth, & Gabriel J. Robbie. (2015). Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. British Journal of Clinical Pharmacology. 81(5). 918–928. 16 indexed citations
10.
DiGiandomenico, Antonio, Ashley Keller, Cuihua Gao, et al.. (2014). A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science Translational Medicine. 6(262). 262ra155–262ra155. 215 indexed citations
11.
Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2014). Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(18). 4747–4757. 55 indexed citations
12.
Borrok, M. Jack, et al.. (2014). pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling. Journal of Biological Chemistry. 290(7). 4282–4290. 78 indexed citations
13.
Notario, Gerard, et al.. (2013). Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis. Pulmonary Pharmacology & Therapeutics. 26(6). 666–671. 29 indexed citations
14.
Long, Hua, Jamese J. Hilliard, Yuru Shi, et al.. (2013). Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia. Antimicrobial Agents and Chemotherapy. 58(2). 1108–1117. 138 indexed citations
15.
Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2012). Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). TPS2618–TPS2618. 2 indexed citations
16.
17.
Kramer, Jeffrey A., Emily O’Neill, Suma Gopinathan, et al.. (2010). Early Toxicology Signal Generation in the Mouse. Toxicologic Pathology. 38(3). 452–471. 20 indexed citations
18.
Yu, Xiang‐Qing & Alan Wilson. (2010). The Role of Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery and Development. Future Medicinal Chemistry. 2(6). 923–928. 16 indexed citations
19.
Wacher, Vincent J., Jeffrey A. Silverman, Susan Wong, et al.. (2002). Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by d-α-Tocopheryl Poly(Ethylene Glycol 1000) Succinate. Journal of Pharmacology and Experimental Therapeutics. 303(1). 308–313. 16 indexed citations
20.
Yu, Xiang‐Qing, et al.. (1996). Effects of Chloral Hydrate on the Cardiorespiratory Response to Hypoxia in Newborn Piglets. Neonatology. 69(3). 146–152. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuling Wu Breakdown of academic impact, for papers by Chandresh Sharma Breakdown of academic impact, for papers by Xiaoxue Ma Breakdown of academic impact, for papers by Supriya Pokkali Breakdown of academic impact, for papers by Thibaud Koessler Breakdown of academic impact, for papers by John G. Chosay Breakdown of academic impact, for papers by David E. Tabor Breakdown of academic impact, for papers by La‐Gen Wan Breakdown of academic impact, for papers by Govindarajan Rajagopalan
Rankless by CCL
2026